Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2013

View Archived Issues

New anticancer agents prepared by Bayer

Wacker develops production process for Metheresis' anticancer candidate

New liposomal nanoparticle formulation tested for activity in ovarian cancer

ALT-801 evaluated in phase I/II trial in patients with urothelial cancer

Spanish researchers disclose new calpain inhibitors

Evestra discloses novel progesterone receptor antagonists

Eli Lilly discloses novel notch signaling inhibitors

FDA accepts umeclidinium bromide/vilanterol NDA

KBP BioSciences synthesizes new antibacterial agents

Intra-Cellular Therapies completes phase I trial of ITI-214

Isis Pharmaceuticals begins phase II/III study of ISIS-TTRRx

Peregrine Pharmaceuticals updates topline data from bavituximab trial

Reduction in tumor burden found with ALT-803 in rodent models

Sucampo launches Rescula in the U.S.

Nippon Kayaku files for additional approval of Hycamtin in Japan

Merck & Co. presents new inhibitors of mTORC1/2

Antiproliferative activity demonstrated for palbociclib in RCC cells

German scientists synthesize novel glycine transporter inhibitors

Stem Cell Therapeutics enters joint-venture agreement

Encouraging immunogenicity results reported from phase III program for NX-1207

C3 Jian completes enrollment for phase I study of candidate for cavity prevention

Phase III data further support efficacy of sofosbuvir

Two novel antibodies enhance response to chemotherapy in NSCLC

Galectin Therapeutics to collaborate with the University of Georgia on drug discovery

Ono files additional indication application for Onoact 50 for injection in Japan

AcelRx Pharmaceuticals provides update on trials of sufentanil NanoTab system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...